Eletriptan Pfizer.

Article Details

Citation

Copy to clipboard

Strijbos PJ, Parsons AA, Fugelli A

Eletriptan Pfizer.

Curr Opin Investig Drugs. 2002 Sep;3(9):1359-68.

PubMed ID

12498013 [ View in PubMed

]

Abstract

Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570]. Eletriptan pharmacology has also been evaluated in vitro in comparison with zolmitriptan (AstraZeneca plc) and naratriptan (GlaxoSmithKline plc) [290116].

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Eletriptan	5-hydroxytryptamine receptor 1D	Protein	Humans	Yes	Agonist	Details